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AntioxidantAbstract The antioxidant and anti-inﬂammatory effects of hexane (HEXA), chloroform
(CHLORO), ethyl acetate (EA) and total alcoholic (T. ALCOH) extracts of Marrubium alysson
in hypercholesterolemic-fed rabbits were evaluated. Hypercholesterolemia was induced in male rab-
bits by high cholesterol diet (HCD) (350 mg/kg) for 8 weeks. Hypercholesterolemic rabbits were
allocated into groups, treated with simvastatin (SIM 5 mg/kg), different extracts of M. alysson at
two doses of 250, 500 mg/kg. A normal control group and an HCD control one were used for com-
parison. Lipid proﬁle, as well as oxidized low density lipoprotein-cholesterol (ox-LDL-C), myelo-
peroxidase activity (MPO) and superoxide anion production (O2), C-reactive protein (CRP)
and monocyte chemoattractant protein-1 (MCP-1) were also evaluated. In addition, histological
examination of ascending aorta was performed. We found dyslipidemia associated with signiﬁcant
increases in ox-LDL-C 123.5 ± 9.8 nmol MDA/mg non-HDL, MPO activity 0.08 ± 0.05 U/
100 mg tissue and O2 production 3.5 ± 0.3 nmol cytochrome C reduced/min/g tissue · 104 in
Antioxidant and anti-inﬂammatory effects of Marrubium alysson 473hypercholerterolemic rabbits. In addition, there was a signiﬁcant increase in CRP 6.6 ± 0.49 lmol/
L and MCP-1 190.9 ± 6.4 pg/ml and its mRNA expression in HCD. Intima appeared thick with
thick plaques surrounding the intima and luminal narrowing. SIM, EA and HEXA extracts of
M. alysson had lipid lowering effect, decrease in ox-LDL-C, MPO, O2, CRP and MCP-1 mRNA
expression with improvement of the pathological picture. M. alysson enhanced the stability of pla-
que, had lipid lowering, anti-inﬂammatory and antioxidant activities.
ª 2013 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Marrubium alysson (M. alysson) is an asterid dicot genus of
Old World aromatic herbs; includes horehound, a genus of
about 40 species of ﬂowering plants in the family Lamiaceae.
It has been used in traditional medicine for various purposes.
It was chosen in our study for its wide distribution in Egypt; it
is reported to have a hypoglycemic effect and inﬂuence on bile
secretion (Blumenthal et al., 2000). It is used also in the treat-
ment of cold, cough and asthma (Louhaichi et al., 2011), as a
diuretic (Caceres et al., 1999), appetizer, astringent, gastropro-
tective (Paula et al., 2011) and antiviral (Edziri et al., 2011).
High cholesterol diet and oxidative stress increase serum to-
tal cholesterol (TC) and LDL-C levels (Jeon et al., 2001). Oxi-
dative modiﬁcation of LDL-C plays a major role in the
pathogenesis of atherosclerosis. The ﬁrst stage of atherogenesis
is characterized by an inﬂux and accumulation of LDL-C in
the intima, followed by recruitment of blood-derived mono-
cytes and lymphocytes to the developing lesion (Steinberg,
2005). Subsequently, LDL-C is oxidized by free radicals;
ox-LDL-C induces a multitude of cellular responses which lead
to vascular dysfunction (Hulten et al., 2005).
MCP-1, a member of the C–C chemokine b subfamily,
causes the recruitment of monocytes, and as such may contrib-
ute to the initiation and maintenance of inﬂammatory reac-
tions in the vascular tissues (Feng et al., 2005). Moreover,
MCP-1 has broader roles in adipocyte physiology than inﬂam-
matory cell recruitment (Sartipy and Loskutoff, 2003). MCP-1
has a direct angiogenic effect on endothelial cells (Low et al.,
2001), it contributes indirectly to inﬂammation by acting on
the liver to produce acute phase proteins (Hug and Lodish,
2005). Among these acute phase proteins is CRP. In recent
years, circulating levels of CRP have been clearly identiﬁed
as a powerful independent risk factor for cardiovascular dis-
eases (Ridker et al., 2000).
Since the involvement of free radicals in the pathophysiol-
ogy of atherosclerosis was proposed, antioxidant supplementa-
tion arose as a potential strategy for the management of this
disease (Hakimog˘lu et al., 2007). The antioxidant activity is
higher in medicinal plants, and because of their perceived
effectiveness, with minimal side effects in clinical experience
and relatively low costs, herbal drugs are prescribed widely
(Miliauskas et al., 2004).
Our study aimed to investigate the potential beneﬁts of to-
tal alcoholic (T. ALCOH), ethyl acetate (EA), chloroform
(CHLORO), hexane (HEXA) extracts of M. alysson for their
antioxidant and anti-inﬂammatory effects in hyper-cholestero-
lemic rabbits in order to verify the activities for which the plant
is used in traditional medicine. Also, the toxicity of different
extracts was evaluated.2. Materials and methods
2.1. Plant collection and preparation of extract
Marrubium alysson was collected from Burg El-Arab at Alex-
andria during April to June 2010. The collected plant was iden-
tiﬁed by Dr. Saneia Kamal, Assistant Professor, Faculty of
Science, Alexandria University. A voucher sample (M.A. – 1)
was kept at the herbarium of the Department of Pharmacog-
nosy, Faculty of Pharmacy, Suez Canal University, Egypt.
The plant was air-dried, ﬁnely powdered (4 kg of the dry
plant), then extracted. The cold maceration technique was used
for extraction of the plant. The powdered plant was soaked in
methanol at room temperature. After seven days, the extract
was ﬁltered under vacuum through Whatman ﬁlter paper
No. 1. The residue was again dipped in methanol for an addi-
tional seven days and ﬁltered thereafter. The ﬁltrate was com-
bined and methanol was evaporated under vacuum, using a
rotary evaporator (Buchi Rotavapor R-200) at 55 C to yield
viscous greenish-colored extract. The quantity of the extract
obtained from M. alysson was 300 g (15%).
2.2. Fractionation
Distilled water was added to the methanol solution in a ratio
of 2:1, followed by successive fractionation with HEXA
(3 · 200 ml), CHLORO (3 · 200 ml) and EA (3 · 200 ml).
Each extract was concentrated separately using vacuum rotary
evaporator and stored at 4 C till use. Two doses of 250 and
500 mg/kg were selected and used in this study. The two doses
were prepared by dissolving appropriate amount of these vis-
cous extracts in 1 ml Tween 20. This was followed by adding
9 ml of 0.9% NaCl to each mixture. The vehicle was obtained
by dissolving 1 ml of Tween 20 in 9 ml of 0.9% NaCl (Irshaid
and Mansi, 2009).2.3. Animals
Eighty-eight male New Zealand White rabbits (2–2.5 kg) were
obtained from the Egyptian Organization for Biological Prod-
ucts and Vaccines. All the animals were housed in individual
cages, left for 7 days prior to the study to acclimatize and re-
ceived standard pellets (15% protein, 2.5% lipid, 15% cellulose,
14% clay, 13% water) (Sezer et al., 2011) during this time. The
animals were maintained on normal light–dark schedule and
temperature 25 ± 3 C throughout the experiment and given
free access to water. All experimental protocols were approved
by the Institutional Animal Care and Use Committee at the
Faculty of Pharmacy, Suez Canal University (Ismailia, Egypt).
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Rabbits were fed either a standard chow diet (control group,
n= 8) or a high-cholesterol diet (HCD, n= 80) consisting of
standard chow supplemented with cholesterol (350 mg/kg/
day) (Oxford Lab, Mumbai, India), dissolved in cottonseed
oil (Egyptian market) for 8 weeks. This dose was proved to in-
duce hypercholesterolemia (Riezebos et al., 1994). Cotton seed
oil is a natural oil that contains a high proportion of polyunsat-
urated fatty acids and proved to have no effects on the tissues
(Mayes, 2000). Hypercholesterolemic rabbits were, then, ran-
domly divided into nine treatment groups. During treatment,
all animals continued to receive the HCD. Animals were treated
once daily by oral gavage with the compounds suspended in
Tween 20 (vehicle) according to the following schedule:
Group 1 (control group): fed a standard pellet 100 g/kg/d.
Group 2 (HCD): fed a HCD and received no additional
treatment.
Group 3 (SIM): HCD received simvastatin (Sigma Chemi-
cal Company, Egypt) at doses of 5 mg/kg (Zhang et al.,
2009).
Group 4 (EA 250): HCD received 250 mg/kg EA extract.
Group 5 (EA 500): HCD received 500 mg/kg EA extract.
Group 6 (HEXA 250): HCD received 250 mg/kg HEXA
extract.
Group 7 (HEXA 500): HCD received 500 mg/kg HEXA
extract.
Group 8 (CHLORO 250): HCD received 250 mg/kg
CHLORO extract.
Group 9 (CHLORO 500): HCD that received 500 mg/kg
CHLORO extract.
Group 10 (T. ALCOHOL250): HCD received 250 mg/kg T.
ALCOHOL extract.
Group 11 (T. ALCOHOL500): HCD received 500 mg/kg T.
ALCOHOL extract.2.5. Toxicity study
The toxicity of four used M. alysson extracts were tested using
four doses (100, 250, 500 and 1000 mg/kg) (three rabbits for
each dose). Three control rabbits were kept under the same
conditions without any treatments. The animals were observed
continuously during the ﬁrst hour, and then every hour for 6 h,
then after 12 and 24 h, and ﬁnally after every 24 h, up to
3 weeks, for any physical signs of toxicity such as writhing,
gasping, salivation, diarrhea, cyanosis, pupil size, any nervous
manifestations, or mortality (Elberry et al., 2011).
2.6. Blood sampling and biochemical analysis
At the end of the study, rabbits were fasted overnight, anesthe-
tized with thiopental sodium (50 mg/kg) (Vogler, 2006). Blood
samples were collected by cardiac puncture. Blood was centri-
fuged at 2000 · g for 15 min after 30 min of collection and
stored at 80 C until assayed.
2.7. Lipid proﬁle
Serum triglycerides (TGs), TC, LDL-C and high density lipo-
protein cholesterol (HDL-C) were measured colorimetricallyusing assay kits from (Stanbio, Texas, USA) according to
the manufacturer instructions using UV–visible spectropho-
tometer (UV-1601PC, Shimadzu, Japan). Additionally athero-
sclerosis index was calculated by the formula: atherosclerosis
index = (serum TCHDL-C) /HDL-C (Hua et al., 2009).
2.8. Plasma oxidized LDL-C (ox-LDL-C)
It was measured according to the principle of (Dujovne et al.,
1994). Brieﬂy, very low density lipoprotein cholesterol
(VLDL-C) and low LDL-C were precipitated from 500 ll of
plasma by 100 ll dextran sulfate/magnesium chloride. The pel-
let was dissolved in 4% saline solution. A volume of the re-dis-
solved precipitate containing 100 lg non HDL-C was mixed
with 4% sodium chloride to give 500 lL of total solution. Cop-
per solution (0.5 mMCuCl2) was added and incubated at 37 C
for 5 h in a shaking water bath. The solution was assayed for
thiobarbituric acid reactive substances as an index for
oxidation.
2.9. Serum CRP and MCP-1
Serum CRP was measured according to the principle of (Ben
Assayag et al., 2009) by ELISA technique using kits purchased
from DIA MED (Belgium). Serum MCP-1 was determined
using Rat MCP-1 ELISA kit (Biosource International, Cali-
fornia, USA) as previously described (Sacerdoti et al., 2005).
2.10. Determination of liver enzymes
Commercial kit Purchased from BioMed Diagnostics (Oregon,
USA), was used for determination of alanine aminotransferase
(ALT), aspartate aminotransferase (AST) and alkaline phos-
phatase (ALP) using UV–visible spectrophotometer (UV-
1601PC, Shimadzu, Japan).
2.11. Measurement of blood urea nitrogen (BUN), creatinine
and total protein
Creatinine and BUN were determined enzymatically using
commercially available kits (Spinreact, Gerona, Spain).Total
Protein was determined using Diamond Diagnostic Kit
(Egypt), according to the manufacturer’s protocol. Serum lev-
els of BUN, creatinine and total protein were determined by
colorimetric methods using UV–visible spectrophotometer
(UV-1601PC, Shimadzu, Japan).
2.12. Processing of aortic tissue
After the end of the experiment, animals in each group were
sacriﬁced, their abdomens and chests were opened and the tho-
racic aorta of each animal was rapidly removed, washed out of
blood using ice-cold (4 C) phosphate-buffered saline
(pH= 7.4) and cleaned of adherent connective tissue. Three
specimens of the ascending aorta, starting just above the left
main coronary artery, was obtained; one specimen was quickly
directed for the analysis of O2, second specimen was placed
in an autoclavable test tube, frozen and stored at 70 C for
biochemical analysis. The other specimen possessed for histo-
pathological examination.
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Assaying of MPO activity was described by (Philip et al.,
2004). Brieﬂy, aortic tissue was homogenized in (1/20 wt., g/
volume ml) homogenization buffer pH (4.7) [0.1 mol/L NaCl,
0.02 mol/L NaHPO4 and 0.015 mol/L sodium ethylenediamine
tetraacetic acid (EDTA)], centrifuge at 260·g for 10 min and
the pellet underwent (dissolved) hypotonic lysis (0.2% NaCl)
solution followed 1 min later by adding an equal volume of
solution containing (1.6% NaCl and 5% glucose). After fur-
ther centrifugation, the pellet was then suspended in resuspen-
sion buffer pH 5.4 (0.05 mol/L NaHPO4 containing 0.5%
hexadecyltrimethylammonium bromide) and re-homogenized.
The suspension was frozen and thawed three cycles in liquid
nitrogen, then centrifuged for 15 min at 3000·g. The pellet
was discarded. MPO activity was assayed by measuring the
change in optical density at 450 nm using tetramethylbenzi-
dine, (1.5 mmol/L) and H2O2 (0.5 mmol/L) (Sigma Chemical
Co) by UV–visible spectrophotometer (UV-1601PC, Shima-
dzu, Japan).
2.14. Assay of superoxide anion (O2) production in aortic
tissue
Tissue O2 was determined according to the modiﬁed method
of (Hassoun and Stohs, 1996). Brieﬂy, aortic tissue was
homogenized in phosphate buffer saline and centrifuged at
16000 · g for 15 min in cooling centrifuge. The supernatant
was added to 0.5 mM cytochrome C (Sigma–Aldrich). This
mixture was re-centrifuged at 3000 · g for 10 min; the superna-
tant fractions were collected for subsequent evaluation using a
UV–visible spectrophotometer (UV-1601PC, Shimadzu,
Japan).
2.15. RT-PCR for detection of MCP-1 mRNA
Total RNA was isolated from aortic tissues using an RNA
extraction kit (Qiagen, Germany). Concentration of the
extracted RNA was measured by NanoDrop ND-1000
(NanoDrop Tech., Wilmington, USA). Speciﬁc primers for
rat MCP-1 cDNA fragment: primer 50-GTC TCT GCA
ACG CTT CTG TGC C0-3 and 50-AGT CGT GTG TTC
TTG GGT TGTGG-30. b-actin primers sense: 50-ATGGAT
GATGATATCGCCGCG-30 antisense50-TGAAGGTAGTTT
CGTGGATGC-30 were used (Sekalska et al., 2007). PCR
was performed using one step RT-PCR kit (Qiagen). Cycling
parameters for amplifying RT products were as follows:
95 C, 1 min; 60 C, 1 min; 72 C, 1 min, for 30 cycles, and
then extended at 72 C for another 5 min. After ampliﬁcation,
PCR products were electrophoresed on 1.2% agarose gel,
stained with ethidium bromide, and photographed by using
the gel documentation system (Bio Doc Analyze, Biometra).
2.16. Quantiﬁcation of the PCR product
The PCR products were then quantiﬁed by using a quantiﬁca-
tion kit (from Promega Corporation, Madison, WI, USA).
This method depends on the puriﬁcation of the PCR using
Promega Wizard PCR preps DNA puriﬁcation kit (Promega
Corporation, Madison, WI, USA). The mixture forquantization consisted of DNA quantiﬁcation buffer, sodium
pyrophosphate, 7 NDPK enzyme solution, T4 DNA polymer-
ase and DNA. All these contents were incubated at 37 C for
10 min. Then, 100 lL of Enliten L/L reagent was added.
Immediately, the reaction was read using a luminometer. The
same steps were done on DNAs of known concentrations pro-
vided by the kit, and a standard curve was performed by plot-
ting the readings of the luminometer against the
concentrations. Then, the readings of the ampliﬁed PCR prod-
ucts of the ﬁve different genes after using the luminometer
were read from the standard curve. The results were expressed
as lg/mg wet tissue (El-Seweidy et al., 2011).
2.17. Histopathological study
Then aortic specimens were ﬁxed overnight in 10% formalde-
hyde, and after routine processing, were embedded in parafﬁn
and cross-sectioned into slices of 4–5 lm thickness at 5 mm
intervals. Sections were subjected to histological techniques
for the general architecture of the aorta. The cross sections
of the aortic tissue were stained with hematoxylin and eosin
(H&E) using an Olympus BX51 light microscope (Tokyo, Ja-
pan). Aortic specimens were stained also with oil red O stain-
ing-to evaluate the atheroma plaque area. Quantitative
histopathological parameters were determined using IMA-
GEJ 1.45F (National Institutes of Health, Bethesda, MD,
USA) for evaluating the percentage of the intima affected
by atherosclerosis (the ratio of the perimeter or the length
of the atherosclerotic lesions/the perimeter of intima), intima
to media ratio and the ratio of the positive surface area occu-
pied by oil red O-stained lesions to the total aortic surface
area. Intimal thickening of each aorta was estimated as an in-
dex of the extent of atherosclerosis by measuring the cross-
sectional area of intima and media. Four to six sections were
used. Fifteen captures per section were taken from each aor-
tic segment. All histological examinations were performed in
a blinded fashion.
2.18. Statistical analysis
All data were expressed as mean ± SEM and analyzed using
the Statistical Package of Social Sciences (SPSS) program ver-
sion 17, (Chicago, IL, USA). For all parameters, comparisons
among groups were carried out using one-way analysis of var-
iance (ANOVA) followed by Dunnat’s multiple comparison
test (Katz, 2006). All P values reported are two-tailed and
P< 0.05 was considered signiﬁcant.3. Results
3.1. Toxicity study
The toxicity study revealed the non-toxic nature of EA,
CHLOR, HEXA and T. ALCOHOL extracts of M. alysson
at doses up to 1000 mg/kg. Rabbits did not show any drug-in-
duced physical signs of toxicity during the whole experimental
period, and no deaths were reported. CHLOR and T. ALCOH
extracts ofM. alysson showed non-signiﬁcant beneﬁcial effects
on all measured parameters.
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atherosclerosis index
Serum lipid proﬁle was signiﬁcantly increased by feeding
HCD. Table 1 shows a signiﬁcant increase in TC, TG and
LDL-C and a non-signiﬁcant decrease in HDL-C in HCD
group as compared to control group. SIM signiﬁcantly amelio-
rated dyslipidemia, while serum HDL-C slightly (but not sig-
niﬁcantly) increased in rabbits treated with SIM. On the
other hand, M. alysson could reduce the serum level of TC,
TG and LDL-C as compared to HCD group. EA extract
showed better results than HEXA extract. Additionally, the
difference in the calculated atherosclerosis index between the
HCD group and the treated groups was signiﬁcant (P< 0.05).
3.3. Effect of M. alysson extracts on plasma ox-LDL-C, aortic
MPO activity and O2 production
Regarding, ox-LDL-C, it signiﬁcantly increased by 2.5-fold at
P< 0.05 in HCD group compared to controls. In conse-
quence, two and three fold signiﬁcant elevation in both aortic
MPO activity and O2 production respectively was detected in
comparison with control group (P< 0.05, Table 2).Table 1 Effect of ethyl acetate and hexane extracts of M. A
hypercholesterolemic rabbits.
Groups TG (mg/dl) TC (mg/dl)
Control 88.2 ± 5.6 100 ± 4.5
HCD 138.4 ± 7.1* 412.5 ± 23.4*
HCD+ SIM 5 mg/kg 110.3 ± 1.7*,# 273.0 ± 27.0*,#
HCD+ EA 250 mg/kg 125,5 ± 3.4*,$ 305.9 ± 34.1*,#
HCD+ EA 500 mg/kg 119.1 ± 3.1*,# 298.0 ± 3.8*,#
HCD+HEXA 250 mg/kg 127.9 ± 5.2*,$ 361.0 ± 14.4*,$
HCD+HEXA 500 mg/kg 121.1 ± 2.9*,# 338.0 ± 14.2*,#,$
TG: triglycerides, TC: total cholesterol, LDL-C: low density lipoprotein
cholesterol diet, SIM: simvastatin, EA: ethyl acetate extract, HEXA: h
expressed as mean ± SEM and analyzed using one-way ANOVA follow
# P< 0.05 compared to HCD group.
$ P< 0.05 compared to simvastatin group, n= 8.
* P < 0.05 compared to control group.
Table 2 Effect of ethyl acetate and hexane extracts ofM. alysson on
rabbits.
Groups ox LDL-C (nmol MDA/
mg non HDL)
Control 49.2 ± 3.9
HCD 123.5 ± 9.8*
HCD+ SIM 5 mg/kg 53.9 ± 1.9#
HCD+ EA 250 mg/kg 62.5 ± 2.6#
HCD+ EA 500 mg/kg 59.2 ± 1.9#
HCD+HEXA 250 mg/kg 71.0 ± 3.6*,#,$
HCD+HEXA 500 mg/kg 69.6 ± 2.8*,#,$
Ox-LDL-C: oxidized low density lipoprotein cholesterol, MPO: mylope
simvastatin, EA: ethyl acetate extract, HEXA: hexane extract. Rabbits w
and analyzed using one-way ANOVA followed by Duncan’s post hoc te
$ P< 0.05 compared to simvastatin group.
@ P< 0.05 compared to EA 500 mg group, n= 8.
* P< 0.05 compared to control group.
# P< 0.05 compared to HCD group.Treatment with SIM signiﬁcantly reduced serum ox-LDL-C
and both MPO activity and O2 production in aortic tissue
compared to HCD group. However, treatment withM. alysson
EA and HEXA extracts signiﬁcantly reduced the all measured
oxidative stress parameters. EA extract (500 mg/kg) showed
signiﬁcantly better results than HEXA extract regarding
MPO activity and O2 production. (P< 0.05, Table 2).
3.4. Effect of M. alysson extracts on serum CRP and MCP-1
In response to oxidative stress, Table 3 shows that, CRP was
signiﬁcantly increased (6.6 ± 0.49 in HCD group vs.
1.3 ± 0.15, P < 0.05), in addition to MCP-1 (190.9 ± 6.4 vs.
69.2 ± 4.1, P< 0.05) as compared with the control group.
In the meanwhile, both SIM andM. alysson extracts could sig-
niﬁcantly decrease these inﬂammatory markers compared to
HCD group (P< 0.05, Table 3).
3.5. Effect of M. alysson extracts on MCP-1 mRNA expression
MCP-1 mRNA was signiﬁcantly enhanced in HCD rabbits in
comparison with the normal control rabbits (750.2 ± 30.2 vs.
150.2 ± 8.9 P< 0.05). Oral administration of SIM signiﬁ-lysson on serum lipid proﬁle and atherosclerotic index in
LDL-C (mg/dl) HDL-C (mg/dl) Atherosclerotic index
96.2 ± 4.7 40.9 ± 1.7 1.48 ± 0.13
143.4 ± 5.2* 37.1 ± 1.0 9.9 ± 0.9*
114.3 ± 3.2*,# 38.0 ± 1.5 6.35 ± 0.7*,#
129.2 ± 4.9*,#,$ 38.1 ± 1.4 8.29 ± 0.34*
123.8 ± 5.6*,# 38.4 ± 1.6 6.9 ± 0.4*,#
134.3 ± 2.6*,$ 36.6 ± 1.4 8.7 ± 0.45*,$
124.7 4.1*,# 37.3 ± 1.3 7.2 ± 1.0*,#
cholesterol, HDL-C: high density lipoprotein cholesterol, HCD, high
exane extract. Rabbits were treated for eight weeks. Results were
ed by Duncan’s post hoc test.
serum ox-LDL-C, aortic MPO and O2 in hypercholesterolemic
MPO (U/100
mg tissue)
O2 (nmol cytochrome C
reduced/min/g tissue · 104)
0.04 ± 0.03 1.09 ± 0.14
0.08 ± 0.05* 3.5 ± 0. 3*
0.05 ± 0.04# 2.4 ± 0.2#
0.06 ± 0.04*,#,@ 3.05 ± 0.2*,@
0.045 ± 0.03# 2.1 ± 0.1#
0.07 ± 0.04*,$,@ 3.2 ± 0.2*,$,@
0.06 ± 0.05*,#,@ 2.8 ± 0.1*,#,@
roxidase O2: superoxide anion, HCD: high cholesterol diet, SIM:
ere treated for eight weeks. Results were expressed as mean ± SEM
st.
Table 3 Effect of ethyl acetate and hexane extracts of M.
alysson on serum CRP, MCP-1 in hypercholesterolemic rabbits.
Groups Serum CRP
(lmol/L)
MCP-1
(pg/ml)
Control 1.3 ± 0.15 69.2 ± 4.1
HCD 6.6 ± 0.49* 190.9 ± 6.4*
HCD+ SIM 5 mg/kg 2.8 ± 0.2*,# 77.8 ± 2.9*,#
HCD+ EA 250 mg/kg 3.5 ± 0.25*,# 92.7 ± 6.2*,#,$
HCD+ EA 500 mg/kg 3.4 ± 0.2*,# 85.3 ± 6.5*,#
HCD+HEXA 250 mg/kg 3.7 ± 0.31*,#,$ 151.5 ± 5.6*,#,$
HCD+HEXA 500 mg/kg 3.5 ± 0.2*,# 150.0 ± 3.9*,#,$
CRP: C-reactive protein, MCP-1: monocyte chemoattractant pro-
tein-1, HCD, high cholesterol diet, SIM: simvastatin, EA: ethyl
acetate extract, HEXA: hexane extract. Rabbits were treated for
eight weeks. Results were expressed as mean ± SEM and analyzed
using one-way ANOVA followed by Duncan’s post hoc test.
$ P< 0.05 compared to simvastatin group, n= 8.
# P< 0.05 compared to HCD group.
* P< 0.05 compared to control group.
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(200.4 ± 8.4 vs. 750.2 ± 30.2, P< 0.05, Fig. 1C). EA and
HEXA (250, 500) extracts of M. alysson showed signiﬁcant
reduction in MCP-1mRNA expression in comparison to
HCD rabbits (P < 0.05), notably, EA extract resulted in a sig-
niﬁcant improvement in MCP-1 mRNA expression compared
to HEXA extract.
3.6. Effect of M. alysson extracts on liver enzyme activity
Feeding of the HCD for 8 weeks resulted in a non-signiﬁcant
increase in serum levels of ALT, AST and ALP compared withFigure. 1 MCP-1 mRNA expression in aortic tissue homogenate of
lane, 2, HEXA 500 (lane 3, normal, lane 4, EA 250, Lane 5, 6 HCD gro
protein-1, N: normal control, HCD: high cholesterol diet, SIM: si
respectively, HEXA 250, 500: hexane extract (250, 500 m/kg) respecti
internal control. (C) Mcp-1 m RNA in lg/mg tissue. Rabbits were tre
analyzed using one-way ANOVA followed by Duncan’s post hoc tes
HCD group, $P< 0.05 compared to SIM group, @P< 0.05 comparethe normal control group. SIM and M. alysson extracts
showed non-signiﬁcant changes in these levels (Table 4).
3.7. Effect of M. alysson extracts on BUN, serum creatinine and
total protein
At the end of the study period, hypercholesterolemic rabbits
showed a non-signiﬁcant change in BUN, serum creatinine
and total protein as compared to normal controls. Oral admin-
istration of SIM andM. alysson extracts did not show any sig-
niﬁcant change in these serum levels (Table 5).
3.8. Effect of M. alysson extracts on histopathological picture
and perimeter ratio and intima/media ratio
The thoracic aorta of rabbits from control group appeared
normal with intact intimal surface. The intima appears thin
and intact with no atherosclerotic plaque on the aorta luminal
surface (Fig. 2A).
In HCD group, H&E stain in all animals of this group re-
vealed thickened intima with thick atherosclerotic plaques ob-
served surrounding the intima and nearly 50% luminal
narrowing in aortic tissue as well as hypertrophic degeneration
of the arterial intima. In all treatment groups, there was a de-
crease in the intimal thickening and plaque formation
(Fig. 2A).
There was a signiﬁcant dose dependent decrease in the
perimeter of the lumen covered by atherosclerotic lesions in
the animals treated with EA extract of M. alysson compared
to HCD non-treated group, HEXA extracts caused a less inhi-
bition of atherosclerosis. However, a further reduction
(P< 0.05, Fig. 2B (of atherosclerotic lesions was observed in
the SIM treated group. SIM resulted in a signiﬁcant decreasestudied groups. (A) RT-PCR. 100 bp marker, lane 1; HEXA 250,
up, lane 7, EA 500, lane 8 SIM.MCP-1: monocyte chemoattractant
mvastatin, EA 250, 500: Ethyl acetate extract (250, 500 m/kg)
vely. (B) b-Actin mRNA expression for each sample was used as
ated for eight weeks. Results were expressed as mean ± SEM and
t. *P < 0.05 compared to control group, #P< 0.05 compared to
d to EA 500 mg group, n= 8.
Table 5 Effect of ethyl acetate and hexane extracts of M. alysson on blood urea nitrogen, serum creatinine and total protein in
hypercholesterolemic rabbits.
Groups BUN (mg/dl) Creatinine (mg/dl) Total protein (g/dl)
Control 29.6 ± 1.4 1.29 ± 0.1 8.0 ± 0.4
HCD 30.9 ± 2.2 1.3 ± 0.17 9.9 ± 0.4
HCD+ SIM 27.6 ± 1.2 1.2 ± 0.08 8.1 ± 0.4
HCD+ EA 250 mg/kg 29.6 ± 0.9 1.3 ± 0.1 7.8 ± 0.3
HCD+ EA 500 mg/kg 32.4 ± 1.7 1.2 ± 0.08 8.2 ± 0.4
HCD+HEXA 250 mg/kg 29.0 ± 1.3 1.2 ± 0.07 7.9 ± 0.5
HCD+HEXA 500 mg/kg 31.2 ± 1.3 1.4 ± 0.08 8.0 ± 0.5
BUN: blood urea nitrogen, HCD: high cholesterol diet, SIM: simvastatin, EA: ethyl acetate extract, HEXA: hexane extract. Rabbits were
treated for eight weeks. Results were expressed as mean ± SEM and analyzed using one-way ANOVA followed by Duncan’s post hoc test.
n= 8.
Table 4 Effect of ethyl acetate and hexane extracts of M. alysson on liver enzymes in hypercholesterolemic rabbits.
Groups Serum ALT (U/L) Serum AST (U/L) Serum ALP (U/L)
Control 27.5 ± 1.4 52.1. ± 2.6 60.1 ± 2.0
HCD 35.7 ± 2.5 60.4 ± 3.1 64.7 ± 2.7
HCD+ SIM 5 mg/kg 37.2 ± 1.8 59.0 ± 2.0 63.1 ± 2.4
HCD+ EA 250 mg/kg 30.5 ± 2.8 55.8 ± 4.1 61.4 ± 2.4
HCD+ EA 500 mg/kg 31.0 ± 2.4 54.5 ± 3.8 60.9 ± 2.3
HCD+HEXA 250 mg/kg 26.4 ± 0.9 57.3 ± 3.7 58.2 ± 2.4
HCD+HEXA 500 mg/kg 29.5 ± 1.9 58.9 ± 2.5 60.5 ± 2.1
ALT: alanine aminotransferase, AST: aspartate aminotransferase, ALP: alkaline phosphatase, HCD, high cholesterol diet, SIM: simvastatin,
EA: ethyl acetate extract, HEXA: hexane extract. Rabbits were treated for eight weeks. Results were expressed as mean ± SEM and analyzed
using one-way ANOVA followed by Duncan’s post hoc test. n= 8.
478 S.S. Essawy et al.in perimeter ratio compared to M. alysson HEXA extract in
the lower dose.
HCD resulted in a signiﬁcant decrease in intima/media ratio
and obliteration in arterial lumen. The intima/media ratio was
signiﬁcantly decreased after SIM treatment to 0.7 ± 0.05 com-
pared with rabbits in the HCD group 1.4 ± 0.1 (Fig. 2C). M.
alysson extracts in both doses induced a reduction in this ratio
also compared to HCD group (P< 0.05, Fig. 2C).
The differences in the degree of atherosclerotic plaque by
cross-sectional microscopic examination of the thoracic aorta
are shown in Fig. 3A. The section showed Oil Red O-stained
particles, mainly foam cells, in the aortic wall intima, with ﬁnd-
ings consistent with those observed in Fig. 3B. SIM and M.
alysson EA and HEXA extracts improved the atherosclerotic
formation.
Average aortic fatty streak accumulation, measured as the
percentage of Oil Red O staining relative to the total area sur-
veyed (Fig. 3B), was signiﬁcantly increased in hypercholester-
olemic non-treated rabbits, while it decreased signiﬁcantly on
SIM administration (44.2%± 3.9 vs. 89.2%± 7.9). M. alys-
son extracts in both doses induced a signiﬁcant reduction in
this ratio also compared to HCD group (P< 0.05, Fig. 3B).4. Discussion
The purpose of this study was to evaluate the antioxidant and
anti-inﬂammatory effects of M. alysson in hypercholesterol-
emic-fed rabbits.
In the animal model used, the hypercholesterolemic diet se-
verely increased plasma TC and LDL-C levels reaching about4 times and 1.5 times the values in control animals respectively,
consistent with the results of another study reported by (Tav-
ridou et al., 2007). HCD induced also a moderate increase in
TGs and a non signiﬁcant decrease in HDL-C, consistent with
the results reported by (Hernandez-Presa et al., 2003; Nachti-
gal et al., 2005).
The signiﬁcant increase in serum ox- LDL-C as well as aor-
tic MPO and O2 levels in the hypercholesterolemic rabbits
represents the effect of hypercholesterolemia on increasing sus-
ceptibility to oxidation (Witztum and Steinberg, 2001). The
oxidatively modiﬁed lipids and their degradation products
are believed to have pro-inﬂammatory, immunogenic, and
cytotoxic properties which contribute to both the initiation
and progression of atherosclerotic lesions (Kato et al., 2009)
as they contribute to the recruitment of monocytes and T cells,
directly or indirectly, via induction of chemokines and endo-
thelial cell adhesion molecules (Witztum and Steinberg, 2001).
In accordance, the increased oxidative stress was accompa-
nied by increased serum MCP-1 and its mRNA expression in
aortic tissue. It was proved that platelet-activating factor lipids
derived from ox-LDL-C stimulate 5-Lipooxygenase expression
in leukocytes and is accompanied by biosynthesis of MCP-1
(Silva et al., 2002).
In the current study, serum CRP was increased suggesting
that the liver had switched to a predominantly inﬂammatory
state responding to high plasma cholesterol as previously de-
scribed (Kleemann et al., 2007). It is well known that CRP is
an excellent marker of inﬂammation in atherosclerosis (Libby
and Ridker, 2004). There is also evidence indicating that high
levels of CRP may be potentially atherogenic (Jialal et al.,
2006).
Figure. 2 Histopathological examination of ascending aortic tissue. (A) The microscopic images of the ascending aortic sections of the
control group appeared normal, with organized intimal surfaces. HCD resulted in huge atherosclerotic plaques surrounding the lumen.
SIM group showed thin and limited atherosclerotic plaque formation. EA and HEXA extracts of M. Alysson showed decrease in intimal
thickening and atherosclerotic plaque formation to a lesser degree than SIM. Scale bar = 100 lm. (B) The perimeter ratio of the studied
groups. (C) Intima/media ratio of the studied groups. HCD: high cholesterol diet, SIM: simvastatin, EA 250, 500: ethyl acetate extract
(250, 500 m/kg) respectively, HEXA 250, 500: hexane extract (250, 500 m/kg) respectively. Rabbits were treated for eight weeks. Results
were expressed as mean ± SEM and analyzed using one-way ANOVA followed by Duncan’s post hoc test. *P< 0.05 compared to
control group, #P< 0.05 compared to HCD group, $P< 0.05 compared to SIM group, @P< 0.05 compared to EA 500 mg group,
n= 8.
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by histopathological picture of increased atherosclerotic pla-
que formation and nearly 50% luminal narrowing in aortic tis-
sue and increased number of inﬂammatory cells and
hypertrophic degeneration of the arterial intima (Steinberg,
2005).
As expected, SIM achieved a 33% and 21% decrease in TC
and LDL-C levels respectively, consistent with previous studies
(Ray et al., 2006). In accordance to (Tavridou et al., 2007),
non-signiﬁcant changes were observed following 4 weeks of
treatment by SIM regarding levels of HDL-C, whereas a sig-niﬁcant but modest decrease was observed in TG levels.
LDL levels in the hypercholesterolemic diet group were higher
than in the control group in spite of treatment with SIM, prob-
ably due to the excessive amount of cholesterol added to the
diet. However, this gave us the opportunity to examine the
beneﬁcial effects of SIM additional to lowering of cholesterol
levels.
The current study showed that treatment with SIM for
4 weeks, revealed a signiﬁcant decrease in serum ox-LDL-C,
aortic MPO level and O2 production compared with HCD
animals. Interestingly, there is clinical evidence that inhibition
Figure. 3 Histopathological examination of ascending aortic
tissue. (A) Microscopic images of the ascending aortic sections of
the control group appeared normal. HCD showed the oil red O-
stained particles of fat deposition. SIM group showed thin and
limited atherosclerotic plaque formation. EA and HEXA extracts
of M. Alysson showed decrease in intimal thickening and
atherosclerotic plaque formation to a lesser degree than SIM.
Scale bar = 100 lm. (B) Quantiﬁcation of aortic fatty streak area
percentage of the studied groups. HCD: high cholesterol diet,
SIM: simvastatin, EA 250, 500: ethyl acetate extract (250, 500 m/
kg) respectively, HEXA 250, 500: hexane extract (250, 500 m/kg)
respectively. Rabbits were treated for eight weeks. Results were
expressed as mean ± SEM and analyzed using one-way ANOVA
followed by Duncan’s post hoc test. *P< 0.05 compared to
control group, #P< 0.05 compared to HCD group, $P< 0.05
compared to SIM group, n= 8.
480 S.S. Essawy et al.of LDL-oxidation can inhibit atherosclerosis independently of
lowering plasma cholesterol levels (Sezer et al., 2011). It has
been suggested that the inhibitory effect of statins on LDL oxi-
dation may result from enhanced removal from plasma of
‘‘aged’’ LDL, which is more prone to oxidation than newly
synthesized LDL (Franzoni et al., 2003). In addition, we found
signiﬁcant reductions of atherosclerotic lesions in animals trea-
ted with SIM compared with HCD animals. To elucidate the
mechanism(s) by which SIM could reduce plaque inﬂamma-
tion, we investigated its effect on MCP-1 which is not only amarker of the development of atherosclerosis, but also of
destabilization of atherosclerotic plaques. Our results showed
that SIM decreased serum MCP-1-and MCP-1 mRNA expres-
sion and so may inhibit monocyte migration. Previous studies
have demonstrated that statins reduce the expression of several
adhesion molecules most likely via increased endothelial nitric
oxide synthase expression and activity (Sasaki et al., 2003;
Nachtigal et al., 2005). SIM also down regulates serum CRP.
Support for our results has come from the report of (Albert
et al., 2001) who found that patients exhibiting lower serum
levels of CRP after statin therapy have better clinical outcomes
than those with higher CRP levels.
By reducing hyperlipidemia and chronically elevated levels
of circulating and local inﬂammatory proteins statins may
minimize the risk of atherosclerotic plaque rupture or arterial
occlusion (Patel et al., 2007; Yu et al., 2012).
The genus Marrubium is represented by 97 species which
are widely spread over the temperate and warm regions. Many
Marrubium species are reported in the literature to be used in
folk medicine (Karioti et al., 2005, 2003).
Similar to SIM group, M. alysson groups – mainly EA ex-
tract- exhibited a low serum level of TC, LDL-C and ox-LDL-
C. Additionally, CRP serum level, found increased in un-
treated rabbits, was also reduced by M. alysson extracts.
CRP, a classical plasma protein marker, is related to cardio-
vascular risk, and its reduction after cholesterol lowering is
associated with improved clinical outcomes (Libby, 2002; Rid-
ker et al., 2005).
It is well known that lesion size is not predictive of plaque
stability in humans, and that inﬂammation is related to plaque
instability (Libby, 2002).
The lipid lowering, antioxidant and anti-inﬂammatory
properties of M. alysson contribute to its anti-atherosclerotic
effect by several different manners. For example, decreased
LDL-oxidation may suppress the expression of adhesion mol-
ecules by endothelial cells and the expression of tissue factor,
colony-stimulating factor, and MCP-1 in macrophages, mole-
cules that modulate the atherosclerotic process which may be
due to the cumulative or synergistic effects of multiple com-
pounds present in the M. alysson extracts such as phenylprop-
anoid glycosides (C¸alis et al., 1992), diterpenes (Savona et al.,
1979) and ﬂavonoids (Karioti et al., 2003).
The results of the current study demonstrated that EA ex-
tract exhibited the major activity followed by HEXA extract,
on the other hand CHLORO and T. ALCOHOL extracts
showed less-signiﬁcant beneﬁcial effects on all measured
parameters (data not shown). A previous work demonstrated
a very preliminary study of the antioxidant activity of different
extracts of M. alysson in vitro using DPPH reagent and anti-
inﬂammatory effect using rat paw edema test, where the study
revealed the activity of all the extracts in different strengths
(Ghazy et al., 2011)
Although hepatotoxicity remains one of the concerns of
statin use and frequent follow-up of liver markers is recom-
mended. The results of the current study revealed a non-signif-
icant increase in serum ALT, AST and ALP in SIM treated
group. To exclude such an adverse effect withM. alysson treat-
ment, we examined the effect of the four extracts ofM. alysson
on serum liver enzymes. EA and HEXA extracts showed a
more favorable effect both on liver transaminasese and ALP
enzymes, indicating a lack of hepatotoxicity. Moreover, there
was no evidence of toxicity of these extracts on the kidney as
Antioxidant and anti-inﬂammatory effects of Marrubium alysson 481manifested by non-signiﬁcant change in BUN, serum creati-
nine and total protein. Overall, the safety proﬁle of M. alysson
extracts on this animal model was good and this is encouraging
given the safety concerns raised for many of the therapeutic
agents aiming at the cardiovascular system.
The results of our study coincide with previous study of the
chemical constituents of M. alysson, where it was proved that
the plant possesses a number of ﬂavonoids accumulated mostly
in the ethyl acetate extract including diosmetin, diosmetin-7-
rhamnoside, chryseriol, luteolin, luteolin-7-rutinoside, acacetin,
acacetin-7-glucoside and quercetin, moreover, all these ﬂavo-
noids showed signiﬁcant free radical scavenging activities when
tested in the same study usingDPPH reagent (Mohamed, 2010).
Our study contains some limitations. First, although lipid-
lowering, antioxidation, anti-inﬂammation and decrease in
plaque size effects of M. alysson have been clariﬁed; the de-
tailed molecular mechanisms underlying these effects require
further investigation. Second, the potential additive effects of
simvastatin and M. alysson on hypercholesterolemia plaque
stabilization need to be tested.
5. Conclusion
Both SIM and M. alysson enhanced the stability of plaque in
rabbits, had lipid lowering, anti-inﬂammation and anti-oxida-
tion activities that may explain the mechanisms underlying the
beneﬁcial effects of SIM and M. alysson.
6. Funding
Natural products from Egyptian plants with hypoglycemic
effect.
Principal investigator for the Egyptian side: Dr. Ghada M.
Hadad.
Awarded by the MENA – Swedish Research Links
Program.
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